In short
This article discusses the clinical trials of VE303, a novel drug containing live bacterial strains, including Bacilli, Cluster XVII, Strain Relative Clostridium_Aq Innocuum. The trials aim to evaluate VE303's effectiveness in preventing recurrent Clostridioides difficile infection (CDI), a serious bacterial infection affecting the digestive system. The study focuses on assessing the drug's safety, efficacy, and impact on patients' quality of life compared to a placebo.
At a glance
- Study Drug
- VE303 (containing multiple live bacterial strains, including Bacilli, Cluster XVII, Strain Relative Clostridium_Aq Innocuum)
- Target Condition
- Prevention of recurrent Clostridioides difficile infection (CDI)
- Study Design
- Randomized, double-blind, placebo-controlled Phase 3 study
- Primary Objective
- Compare CDI recurrence rate at Week 8 between VE303 and placebo groups
- Key Secondary Objectives
- Assess safety, evaluate CDI recurrence rates at Weeks 12 and 24, measure VE303 bacterial strain detection and abundance, assess quality of life and CDI symptoms
- Participant Groups
- Recurrent CDI (rCDI) and high-risk primary CDI (pCDI-hr) populations
- Treatment Duration
- 14 days of oral VE303 or placebo administration
- Follow-up Period
- 24 weeks
- Key Inclusion Criteria
- Age ≥12 years (or ≥18 in some countries), laboratory-confirmed CDI episode, completion of standard antibiotic therapy
- Key Exclusion Criteria
- Chronic diarrhea, pregnancy, certain medical conditions (e.g., celiac disease, inflammatory bowel disease), recent use of probiotics or other CDI treatments
What is VE303?
VE303 is an investigational medicine being developed to prevent the recurrence of Clostridioides difficile infection (CDI). It is a capsule that contains live bacteria, specifically designed to restore the balance of good bacteria in your gut. VE303 is made up of eight different types of beneficial bacteria, including one called Bacilli, Cluster XVII, strain relative Clostridium_AQ innocuum.
How does VE303 work?
VE303 works by introducing helpful bacteria into your digestive system. These bacteria are thought to help fight off the harmful C. difficile bacteria that cause infection. By restoring a healthy balance of bacteria in your gut, VE303 aims to prevent C. difficile from coming back after you've been treated with antibiotics.
What condition does VE303 treat?
VE303 is being studied for the prevention of recurrent Clostridioides difficile infection (CDI). CDI is a serious intestinal infection that can cause severe diarrhea, abdominal pain, and in some cases, life-threatening complications. It often occurs after a person has taken antibiotics, which can disrupt the normal balance of bacteria in the gut. Some people experience repeated episodes of CDI, which is called recurrent CDI.
Clinical Trial Details
A clinical trial called the RestoratiVE303 Study is currently underway to test how well VE303 works compared to a placebo (a capsule with no active ingredients). This is a Phase 3 study, which means it's in an advanced stage of testing. The main goal of the study is to see if VE303 can reduce the number of people who experience a recurrence of CDI within 8 weeks of treatment.
Who can participate in the VE303 trial?
The trial is looking for participants who meet certain criteria, including:
- People aged 12 years or older (18 years or older in some countries)
- Those who have had at least one previous episode of CDI in the last 6 months
- Individuals who have recently completed a course of antibiotics for CDI
There are also specific criteria for older adults (75 years or older) or those with certain risk factors. Your doctor can help determine if you're eligible for the study.
What to expect during the trial
If you participate in the trial, here's what you can expect:
- You'll be randomly assigned to receive either VE303 or a placebo.
- You'll take the assigned treatment (VE303 or placebo) orally for 14 days.
- You'll be followed up for 24 weeks to see if you experience any recurrence of CDI.
- Throughout the study, you'll have various tests and assessments to monitor your health and the effectiveness of the treatment.
Potential Benefits and Risks
While VE303 shows promise in preventing recurrent CDI, it's important to remember that it's still being studied. Potential benefits may include a reduced risk of CDI recurrence, but as with any medical treatment, there may also be risks or side effects. The study team will monitor participants closely for any adverse effects.
If you're interested in learning more about VE303 or the RestoratiVE303 Study, talk to your healthcare provider. They can provide more information and help determine if participating in the trial might be right for you.